NHS-IL12 for Solid Tumors

Summary

NHS-IL12 for Solid Tumors is a clinical trial^[1].

Key Facts

• NHS-IL12 for Solid Tumors is in the country of United States^[2].
• NHS-IL12 for Solid Tumors's instance of is recorded as clinical trial^[3].
• NHS-IL12 for Solid Tumors's start time is recorded as +2011-12-12T00:00:00Z^[4].
• NHS-IL12 for Solid Tumors's end time is recorded as +2020-01-01T00:00:00Z^[5].
• NHS-IL12 for Solid Tumors's sponsor is recorded as National Cancer Institute^[6].
• NHS-IL12 for Solid Tumors's main subject is recorded as maximum tolerated dose^[7].
• NHS-IL12 for Solid Tumors's main subject is recorded as pharmacokinetics^[8].
• NHS-IL12 for Solid Tumors's main subject is recorded as cancer^[9].
• NHS-IL12 for Solid Tumors's main subject is recorded as sarcoma^[10].
• NHS-IL12 for Solid Tumors's main subject is recorded as carcinoma^[11].
• NHS-IL12 for Solid Tumors's main subject is recorded as mesenchymoma^[12].
• NHS-IL12 for Solid Tumors's number of participants is recorded as {'unit': '1', 'amount': '+83'}^[13].
• NHS-IL12 for Solid Tumors's title is recorded as First In-Human Phase I Trial of NHS-IL12 in Patients With Metastatic Solid Tumors^[14].
• NHS-IL12 for Solid Tumors's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[15].
• NHS-IL12 for Solid Tumors's ClinicalTrials.gov ID is recorded as NCT01417546^[16].
• NHS-IL12 for Solid Tumors's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+100'}^[17].
• NHS-IL12 for Solid Tumors's research intervention is recorded as intravenous immunoglobulin^[18].
• NHS-IL12 for Solid Tumors's clinical trial phase is recorded as phase I clinical trial^[19].
• NHS-IL12 for Solid Tumors's research site is recorded as United States National Institutes of Health^[20].
• NHS-IL12 for Solid Tumors's study type is recorded as interventional study^[21].